- Home
- AMRX vs ACAD Comparison
AMRX vs ACAD Comparison
Compare AMRX & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMRX
- ACAD
- Stock Information
- Founded
- AMRX 2002
- ACAD 1993
- Country
- AMRX United States
- ACAD United States
- Employees
- AMRX N/A
- ACAD N/A
- Industry
- AMRX Biotechnology: Pharmaceutical Preparations
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- AMRX Health Care
- ACAD Health Care
- Exchange
- AMRX Nasdaq
- ACAD Nasdaq
- Market Cap
- AMRX 2.3B
- ACAD 2.5B
- IPO Year
- AMRX N/A
- ACAD 2004
- Fundamental
- Price
- AMRX $7.82
- ACAD $22.71
- Analyst Decision
- AMRX Strong Buy
- ACAD Buy
- Analyst Count
- AMRX 4
- ACAD 16
- Target Price
- AMRX $11.50
- ACAD $27.00
- AVG Volume (30 Days)
- AMRX 1.6M
- ACAD 1.6M
- Earning Date
- AMRX 08-08-2025
- ACAD 08-05-2025
- Dividend Yield
- AMRX N/A
- ACAD N/A
- EPS Growth
- AMRX N/A
- ACAD N/A
- EPS
- AMRX N/A
- ACAD 1.37
- Revenue
- AMRX $2,830,186,000.00
- ACAD $996,283,000.00
- Revenue This Year
- AMRX $9.84
- ACAD $13.39
- Revenue Next Year
- AMRX $7.33
- ACAD $10.59
- P/E Ratio
- AMRX N/A
- ACAD $16.65
- Revenue Growth
- AMRX 13.42
- ACAD 22.42
- 52 Week Low
- AMRX $6.29
- ACAD $13.40
- 52 Week High
- AMRX $9.48
- ACAD $25.23
- Technical
- Relative Strength Index (RSI)
- AMRX 54.91
- ACAD 66.04
- Support Level
- AMRX $7.72
- ACAD $21.35
- Resistance Level
- AMRX $8.11
- ACAD $22.69
- Average True Range (ATR)
- AMRX 0.26
- ACAD 0.76
- MACD
- AMRX 0.05
- ACAD -0.13
- Stochastic Oscillator
- AMRX 72.12
- ACAD 70.76
About AMRX Amneal Pharmaceuticals Inc.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE - It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.